View Older Stories View More Recent Stories

Oct 2, 2017 01:03AM ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
Sep 14, 2017 01:02AM ABLYNX ANNOUNCES WARRANT EXERCISE
Sep 7, 2017 01:03AM ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON
Aug 30, 2017 01:03AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Aug 30, 2017 01:02AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Aug 24, 2017 01:03AM ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE
Aug 17, 2017 01:02AM ABLYNX WILL ANNOUNCE ITS 2017 HALF YEAR RESULTS WITH WEBCAST ON 24 AUGUST 2017
Aug 11, 2017 01:02AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 26, 2017 01:02AM ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
Jul 24, 2017 01:02AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 20, 2017 01:01AM ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES
Jul 17, 2017 02:09AM ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR
Jul 6, 2017 01:04AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jun 27, 2017 01:04AM ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA
Jun 26, 2017 01:02AM ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS
Jun 16, 2017 01:01AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jun 14, 2017 01:01AM ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY
Jun 13, 2017 01:01AM ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER
May 22, 2017 01:01AM NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT
May 16, 2017 01:03AM ABLYNX TO PRESENT AT UPCOMING USA INVESTOR CONFERENCES
May 11, 2017 01:04AM ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE
May 2, 2017 01:01AM ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP
Apr 21, 2017 01:03AM ABLYNX ANNOUNCES WARRANT EXERCISE
Mar 6, 2017 01:01AM ABLYNX'S PARTNER, MERCK KGaA, HAS PRESENTED NEW DATA FROM A PHASE Ib PSORIASIS STUDY OF THE BI-SPECIFIC ANTI-IL-17A/F NANOBODY AT THE ANNUAL AAD CONFERENCE
Feb 23, 2017 01:01AM ABLYNX ANNOUNCES 2016 FULL YEAR RESULTS
Feb 16, 2017 01:01AM ABLYNX WILL ANNOUNCE ITS 2016 FULL YEAR RESULTS WITH WEBCAST ON 23 FEBRUARY 2017
Feb 9, 2017 01:01AM ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
Feb 6, 2017 01:01AM ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB, ITS ANTI-vWF NANOBODY, FOR THE TREATMENT OF aTTP
Jan 26, 2017 01:10AM ABLYNX'S PARTNER, MERCK KGaA, REPORTS ENCOURAGING RESULTS WITH THE BI-SPECIFIC NANOBODY ANTI-IL-17A/F (M1095) IN A PHASE Ib CLINICAL STUDY IN PATIENTS WITH PSORIASIS
Jan 24, 2017 01:04AM VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX
Jan 18, 2017 01:06AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jan 11, 2017 11:49AM ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS IN HOSPITALISED INFANTS
Jan 5, 2017 01:19AM ABLYNX TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Dec 28, 2016 01:06AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 23, 2016 01:07AM FMR LLC ANNOUNCE 9.16% SHAREHOLDING IN ABLYNX
Nov 30, 2016 01:06AM ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK
Nov 23, 2016 01:08AM ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2016 AND A YEAR-TO-DATE BUSINESS UPDATE
Nov 18, 2016 01:05AM FMR LLC ANNOUNCE 9.10% SHAREHOLDING IN ABLYNX
Nov 10, 2016 01:21AM ABLYNX ANNOUNCES WARRANT EXERCISE
Nov 9, 2016 01:15AM ABLYNX TO PRESENT AT THE JEFFERIES LONDON HEALTHCARE CONFERENCE 2016
Oct 21, 2016 01:03AM ABLYNX ANNOUNCES WARRANT EXERCISE
Oct 20, 2016 01:05AM ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
Oct 12, 2016 01:04AM ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.
Oct 11, 2016 01:05AM FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX
Oct 10, 2016 01:15AM ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP
Sep 29, 2016 01:05AM ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP
Sep 15, 2016 01:07AM ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.
Aug 25, 2016 01:10AM ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE
Aug 17, 2016 01:09AM ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016
Aug 12, 2016 01:06AM ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.
View More Recent Stories View Older Stories